Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion

Adam Ofri¹,², Danika Zuidersma¹, Connie I. Diakos¹,², Amanda Stevanovic³, Matthew Wong⁶, Samriti Sood¹, Jaswinder S. Samra³,⁴, Anthony J. Gill³,¹⁰,¹² and Anubhav Mittal³,⁸,⁹,¹⁰,¹³

¹Department of Surgery, Sir Charles Gairdner Hospital, Nedlands, Australia, ²St Vincent’s Clinical School, University of New South Wales, Sydney, Australia, ³Kolling Institute of Medical Research, University of Sydney, Sydney, Australia, ⁴Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia, ⁵Department of Medical Oncology, Nepean Cancer Care Centre, Nepean, Australia, ⁶Central Coast Cancer Centre, Gosford Hospital, Gosford, Australia, ⁷Department of Breast Surgery, Royal North Shore Hospital, St Leonards, Australia, ⁸Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, St Leonards, Australia, ⁹Australian Pancreatic Centre, St Leonards, Sydney, Australia, ¹⁰Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ¹¹School of Medicine, Macquarie University, Sydney, Australia, ¹²NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia, ¹³School of Medicine, University of Notre Dame, Sydney, Australia

Background: Synchronous cancers are rarely detected when working-up a patient for a primary cancer. Neoadjuvant management of synchronous breast and pancreatic cancers, without a germline mutation, has yet to be discussed. Two patients were diagnosed with synchronous breast and pancreatic cancers at our institution over the last decade. A literature review was performed to evaluate the current evidence stance.

Results: The first patient was 61-years old and diagnosed with a HER2+ breast cancer. The second patient was 77-years old and diagnosed with a Luminal B breast cancer. The inability to provide concurrent breast and pancreatic neoadjuvant therapy for the HER2+ patient, resulted in upfront surgery. The second patient was able to have both cancers treated simultaneously - neoadjuvant chemotherapy to the pancreas, and neoadjuvant endocrine therapy to the breast.

Discuss: There is no single neoadjuvant regimen that treats both pancreatic and breast cancer. The differences in breast cancer sub-types impacted our neoadjuvant options. Our recent experience led us to the hypothesis that breast cancer care dictates treatment, while pancreatic cancer determines survival. There is a significant paucity in the literature regarding synchronous breast and pancreatic cancer.

Keywords: pancreatic cancer, breast cancer, synchronous, non-germline, neoadjuvant treatment

INTRODUCTION

The management of operable pancreatic cancer patients is complex and multifaceted. The typical pancreatic cancer presentation is late, with less than 20% up-front surgical candidates. The term “borderline” resectable has been used with varying definitions. The underpinning notion being
that surgery is feasible, however the likelihood of incomplete resection is high (1–3). For these cases, downstaging with neoadjuvant and repeat staging is currently recommended (4). Dual malignancy can significantly complicate the management of patients.

The presence of synchronous pancreatic and breast cancers is rare, having been described in a handful of case reports, resulting in management difficulty (5, 6). Over the last decade, the genetics associated with pancreatic cancer has been intricately assessed (7) Some well-known cancer gene germline mutations have been identified in patients with pancreatic cancer, including BRCA1/2, PALB2, STK11, PRSS1, SPINK1 and ATM. Pathogenic mutations are identified in approximately 15% of pancreatic adenocarcinoma patients; with germline BRCA mutations accounting for more than 50% of these mutations (8). Somatic mutations in the homologous recombination pathway mimicking germline BRCA1/2 loss are termed “BRCAness” or “BRCA-like” genes (9, 10). However, it is uncertain whether germline mutation treatments are as effective (11, 12).

BRCA1 and BRCA2 are associated with the DNA repair pathway and together, are the most common genetic cause for breast cancer, accounting for approximately 5% of all cases. Patients with BRCA1/2 mutations have a 72% and 69% lifetime risk of developing breast cancer respectively, with increased ovarian cancer risks. BRCA1 also increases the relative risk (RR) for pancreatic cancer by 2 to 4-fold, where BRCA2 increases RR by 3 to 8-fold (13).

The 5-year survival rate for breast cancer in Australia is approximately 91% (14). Nodal status greatly impacts 5-year survival rates, 96% for node-negative, 80% for node positive. Comparatively, pancreatic cancer is an aggressive malignancy with a reported Australian 5-year survival rate of 10.7% (15). Given the significantly different survival rates, one would expect that pancreatic cancer management would drive patient care.

However, our recent experience led us to the hypothesis that breast cancer care may dictate treatment, while pancreatic cancer determines survival. Here we present our two cases and review the current extent of literature for synchronous breast and pancreatic cancers.

**METHODS**

From January 2020 until January 2021, two patients were diagnosed with synchronous pancreatic and breast cancers in the Upper Gastrointestinal Surgery Department of Royal North Shore Hospital, NSW, Australia, a tertiary referral centre for pancreatic cancer care. Ethical approval was obtained from the Northern Sydney Local Health District Human Research and Ethics Committee. Of the two patients, one underwent upfront surgery and the other received neoadjuvant chemotherapy. Given the rarity of synchronous pancreatic and breast cancer, a comprehensive literature review was performed. A literature search was performed using the PubMed, EMBASE, Medline, Web of Science, and Cochrane Library databases for studies published between 1 January 1990 and 31 August 2021. The following MeSH terms and their combinations were searched: (breast +/- cancer/neoplasm/tumor/tumour) and (pancreas/pancreatic +/- cancer/neoplasm/tumor/tumour) and (synchronous). Peer-reviewed papers with English abstracts were all reviewed. Two authors (AO & DK) independently reviewed the titles and abstracts to screen and extract relevant articles.

**RESULTS**

**Case 1 – Surgery First**

A 61-year-old woman presented with ongoing epigastric pain post cholecystectomy. An MRI scan identified an intraductal papillary mucinous neoplasm (IPMN). Due to significant patient anxiety and initial refusal for an endoscopic ultrasound (EUS), an FDG-PET was performed, identifying FDG uptake in a lesion in the pancreatic head, as well as a lesion in the upper quadrant of the left breast. CNB of the breast lesion confirmed Grade 3 IDC, hormone receptors negative, amplified for HER-2, with a Ki67 of 40%. Axillary lymph node FNAB was positive for breast carcinoma. EUS of the pancreas identified a 1.5 cm mass in the neck of the pancreas and a lesion in the tail of the pancreas, with FNA confirming PDAC in both lesions. Full mutation search for BRCA1/2 and PALB2 was negative.

This case was discussed at both the Breast and Pancreas multi-disciplinary meetings, with the consensus recommendation made for up-front surgery with adjuvant chemotherapy. In this scenario, there were two aggressive malignancies with no significant overlap of active systemic treatments that would provide benefit in both cancers; therefore, the concern was for potential progression of one or both malignancies during a period of neoadjuvant systemic treatment, that would ultimately render one or both malignancies, inoperable.

The patient underwent an uneventful total pancreatectomy and simultaneous mastectomy and axillary nodal clearance. Histopathology confirmed two completely excised cancers - a Stage IIa pancreatic ductal adenocarcinoma with 1/29 lymph nodes, and a 19 mm breast cancer Grade 3 IDC with 23/25 positive axillary nodes. She was subsequently treated with Carboplatin, Paclitaxel and trastuzumab as adjuvant systemic treatment; this regimen was selected given evidence of activity in both malignancies for the chemotherapy component, with the trastuzumab directed towards the Her2-positive early breast cancer (EBC).

Unfortunately, a PET performed 5 months post operatively indicated pancreatic recurrence in the middle of the pancreatic bed, a poor prognostic indicator. She is currently undergoing chemotherapy with the FOLFIRINOX (oxaliplatin, irinotecan and 5-FU) regimen, with RT to the pancreatic bed, as salvage intent treatment.
Case 2 – Neoadjuvant Chemotherapy First
The second patient was a 77-year-old woman, referred from her gastroenterologist after being investigated for weight loss, anorexia, and abdominal pain over 6 months. CT imaging identified an ill-defined hypodense mass at the junction of the body and neck of the pancreas with abnormally appearing lymph nodes, as well as left axillary lymphadenopathy. Breast ultrasound identified 2 lesions in the left breast, irregularly hypoechoic and in close proximity: 19 and 8 mm in size. CNB of the breast lesions confirmed Grade 2 IDC that was hormone receptor positive, HER-2 negative on IHC, with a Ki67 of 60%. The patient’s family history was unremarkable and genetic testing was negative for any known mutations.

The multi-disciplinary team recommended neoadjuvant chemotherapy directed towards the pancreatic malignancy with neo-adjuvant endocrine therapy for the breast cancer. She was commenced on the FOLFIRINOX chemotherapy regimen and Letrozole (an aromatase inhibitor, given her post-menopausal state).

She tolerated her chemotherapy regimen well. Her immediate post-chemotherapy PET-CT indicated resolution of FDG uptake in the breast and the axillary nodes, with reduction in FDG avidity to the pancreas. During her work up for operative intervention, she developed increasing Ca 19.9 levels, with a repeat PET-CT indicated liver metastases. Subsequently she was re-started on further chemotherapy and not deemed a surgical candidate.

DISCUSSION
We present here a series of two women presenting with synchronous operable breast and pancreatic malignancies, to a specialist multi-disciplinary quaternary referral centre. The management of these two cases differed, predominantly due to the breast pathology. In the first case, the inability to provide appropriate dual-spectrum neoadjuvant treatment (due to HER-2 amplification) resulted in up-front surgery. In the second case, due to the hormone receptor positivity, we were able to provide concurrent pancreatic-NACT and neo-adjuvant endocrine treatment (NET) to the breast. Unsurprisingly, the outcomes of both cases were determined by the progression of the pancreatic adenocarcinoma, which is typically the more aggressive of the two tumour types.

Literature Review
After a comprehensive review of the literature, only 6 studies were found to have discussed synchronous pancreatic and breast cancer (Table 1). Two papers were in Japanese with English abstracts (16, 17). Both described synchronous breast and pancreatic cancer, with one case where the pancreatic cancer had metastasized to the liver and peritoneum. A case report by Kim et al., discussed a patient diagnosed with breast and pancreatic synchronous cancers, as well as concurrent thyroid and gastrointestinal stromal cancer (18). One letter to the editor discussed a patient with prostatic cancer, who then developed primary breast and pancreatic cancer, as well as pulmonary and bone metastasis of unknown origin (20). Unek et al. reported on a male patient who developed synchronous breast and pancreatic cancer, on a background of previously treated testicular cancer (19). The only germline case report has been by Castro et al. who discussed synchronous breast and pancreatic cancer in a BRCA2 mutation (5).

Of the available literature, only one case discussed NACT. This was in the regimen of gemcitabine and nab-paclitaxel. Adjuvant chemotherapy varied in the other 3 cases; doxorubicin-cisplatin followed by gemcitabine-NAB paclitaxel, 5-Fu and Gemcitabine, and carboplatin-taxotere. There was no discussion regarding the decision making behind any of the chemotherapy regimens in any of the papers.

Neoadjuvant Chemotherapy Indications
At our institution, the default pancreatic cancer management sequence is neoadjuvant chemotherapy followed by surgery for tumours >2 cm and/or node positive. Current international guidelines are varied regarding this stance. The National Comprehensive Cancer Network (NCCN) suggest NACT usage in high-risk potentially resectable (borderline) tumours, however the American Society of Clinical Oncology (ASCO) guidelines suggest against NACT if tumours are potentially resectable (21, 22). The European Society for Medical Oncology (ESMO) guidelines do not discuss NACT in potentially resectable Pancreatic cancers (23).

There are currently multiple indications for neoadjuvant breast cancer treatment– ranging from receptor status, tumour size, nodal involvement, as well as desire to perform breast conservation therapy (24–27). NACT can result in decreasing tumour size to facilitate breast conservation therapy (BCT), potentially de-escalate axillary surgery, and maximize the potential aesthetic outcomes dependent on tumour location. Landmark studies, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 and B-27, did not identify any statistically significant benefit for neoadjuvant chemotherapy (NACT) compared to adjuvant CTX (28). However, they have shown that NACT patients that achieved a complete pathological response (pCR) have statistically superior disease-free survival (DFS) and overall survival (OS).

Neoadjuvant Chemotherapy Regimens
Our preferred chemotherapy regimen in pancreatic cancer is FOLFIRINOX, or a modified FOLFIRINOX, dependent on a patient’s European Cooperative Oncology Group (ECOG) performance status. The preference for FOLFIRINOX over Gemcitabine ± capecitabine is based off adjuvant studies that have shown superior survival rates for FOLFIRINOX compared to Gemcitabine, and from neoadjuvant FOLFIRINOX studies showing higher rates of R0 resections and favourable median overall survival (29, 30).

Current breast cancer NACT typically involves a regimen containing an anthracycline and taxane (31). In patients whom anthracyclines are contraindicated, a regimen of CMF can be offered. From this backbone, additions are recommended depending on the breast cancer subtype. In HER-2 positivity, the addition of HER-2 directed therapy,
| Authors, Year | Case | Breast Cancer | Pancreatic cancer | Treatment | Outcome |
|---------------|------|---------------|-------------------|-----------|---------|
| Nakanishi et al (16), 2021 | 78y female - synchronous left breast cancer and pancreatic cancer | 48 mm IDC, with nodal involvement, NFI (T2N1M0) | 30 mm borderline resectable pancreatic body adenocarcinoma | 1. NAC: gemcitabine and nab-paclitaxel. Stable breast cancer and partial response to pancreatic cancer 2. Pancreato-splenectomy with portal vein and gastroduodenal artery resection and reconstruction + left mastectomy with axillary lymph node dissection 3. Fluorouracil, epirubicin and cyclophosphamide | No recurrence noted |
| Takada et al (17), 2018 | 67y male - synchronous left breast and pancreatic cancer (with liver and peritoneal metastases) | 28 mm, IDC, TNBC (T2N0M0) | 40 mm unresectable pancreatic tail cancer | 1. Palliation due to hepatic failure secondary to pancreatic tumour growth | Died |
| Castro et al (5), 2016 | 41y female - synchronous locally advanced left breast cancer and pancreatic cancer, BRCA2 mutation | 75 mm Grade 2 IDC (ER/PR+, HER2-) with HG-DCIS, 8/23 LN (T3N2aM0) | 26 mm resectable pancreatic tail adenocarcinoma | 1. Left modified radical mastectomy 2. Laparoscopic, hand assisted splenectomy, distal pancreatectomy, lymphadenectomy and bilateral salpingo-oophorectomy 3. Adjuvant chemotherapy: doxorubicin-cisplatin followed by gemcitabine-NAB paclitaxel 4. Radiotherapy (post-mastectomy and upper abdominal) + aromatase inhibitor 5. For consideration of Olaparib therapy | Alive at time of publication |
| Kim et al (18), 2013 | 73y female - synchronous left breast cancer, pancreatic cancer, papillary carcinoma of the thyroid and GIST. | Multiple IDC, NFI (TxNxMx) | 18 mm unresectable pancreatic body adenocarcinoma with ductal dilatation and coeliac axis invasion | 1. Patient refused aggressive treatment including surgery 2. Agreed for treatment of the breast cancer and GIST (hormone therapy and chemotherapy): Letrozole + imatinib 3. Supportive treatment for thyroid and pancreatic cancer | Died 8 months after diagnosis |
| Unek et al (19), 2008 | 50y male - synchronous right breast cancer and pancreatic cancer. Background of previously treated mixed germ cell testicular tumour 15 years prior | 11 mm Grade 1 IDC, ER+, PR-, HER2-, LVI+ (T4bN0M0) | 25 mm resectable pancreatic head adenocarcinoma | 1. Surgery: Whipple procedure and right mastectomy 2. Radiotherapy + Chemotherapy- Radiotherapy: to pancreatic region and chest wall - Chemotherapy: 5-Fu + Gemcitabine. Patient refused after 6 cycles due to metastatic spread | Died 10 months after diagnosis |
| Morgan et al (20), 2008 | 69y male - 2 primary right breast cancers and primary pancreatic cancer with liver metastasis Two months post starting therapy for prostate adenocarcinoma | 25 mm + 15 mm Grade 2 IDC, 0/25 LN (T2N0M0) | 30 mm unresectable pancreatic body and tail adenocarcinoma with vascular invasion with liver metastases | 1. Total right mastectomy 2. Chemotherapy: carboplatin-taxotere, 15 cycles 3. Zidovudine, monthly, 8 cycles 4. LHRH for prostate cancer continued 5. Chemotherapy second regimen due to disease progression: gemcitabine and oxaliplatin 6. Worsening ascitic effusion with pain, dyspnoea and haematologic toxicity: Regimen changed to gemcitabine alone | Died 17 months after diagnosis |

5-Fu, Fluorouracil; ER, estrogen receptor; GIST, Gastrointestinal Stromal Tumour; HG-DCIS, high-grade ductal carcinoma in-situ; IDC, invasive ductal carcinoma; LN, lymph nodes; LVI, lymphovascular invasion; NAC, neoadjuvant chemotherapy; NFI, no further information; PR, progesterone receptor; TNBC, triple negative breast cancer.
trastuzumab +/- pertuzumab, have been shown to significantly improve pCR, event free survival and overall survival (32, 33). In triple negative breast cancer (TNBC) the addition of carboplatin is recommended, weighing the risk to benefit.

For hormone receptor positive patients, neoadjuvant endocrine therapy (NET) has shown similar response rates, and rates of BCT, compared to NACT in post-menopausal women, with less side effects (34). In post-menopausal women, when comparing CTX with AI monotherapy ( exemestane, anastrozole) – there is comparable median time until clinical response, similar pCR rates and no difference in LRR (35). Survival data at this stage though is not available. The data available regarding its efficacy in pre-menopausal is limited but suggests worse response rates relative to CTX (36). As such, current guidelines advocate for NET in pre-menopausal women in a clinical trial setting only.

In HER-2 breast cancer patients ≥ T1c, NACT is recommended with sequential trastuzumab. In our patient the delivery of NACT with HER-2 directed therapy, typically AC-T and Trastuzumab, was inappropriate due to the lack of pancreatic treatment. The inability to treat the pancreatic and breast malignancy concurrently resulted in the necessity for upfront surgery. Trastuzumab can be delivered with FOLFIRINOX, as in HER2+ gastric cancers, however FOLFIRINOX has not shown any efficacy in breast cancer. Synchronous pancreatic and breast cancers, though rare, has had literature identifying breast cancer progression whilst on FOLFIRINOX for metastatic pancreatic cancer (37).

Directed HER-2 therapy alone is not appropriate, as shown in the KRISTINE trial (38). This randomized, multi-centre, phase 3 trial failed to prove comparative pCR rates for HER-2 targeted treatment alone (trastuzumab emtansine plus pertuzumab) to traditional NACT plus dual HER-2 targeted treatment (docetaxel, carboplatin, trastuzumab and pertuzumab).

Neoadjuvant Treatment Adjuncts in Breast Cancer

Directed management of HR-positive, HER2-negative early breast cancer, relies on anti-estrogen therapy. In advanced HR-positive, HER2-negative breast cancers, the addition of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors has become the new standard of care. Their usage in EBC though has had mixed standard of care. Their usage in EBC though has had mixed results (39–42). Two recent studies have shown statistically significant positive outcomes involving the usage of Abemaciclib, in both neoadjuvant and adjuvant delivery (43, 44). The monarchE study was a phase 3 study that evaluated adjuvant Anastrozole ± Abemaciclib, in post-menopausal HR-positive, HER2-negative patients with EBC. Results demonstrated superior 2-year invasive disease-free survival with the addition of Abemaciclib (92.2% versus 88.7%, p = 0.01).

The neoMONARCH phase 2 study compared two-week usage of Abemaciclib alone, Anastrozole alone or Abemaciclib and Anastrozole, in post-menopausal women in the neoadjuvant setting. The primary end point, Ki67 expression change, was elevated in treatment arms including Abemaciclib (Abemaciclib alone 91%, Abemaciclib and Anastrozole 93%, Anastrozole alone 63%). A complete pathological response (pCR) was achieved in 4% of the cohort that received Abemaciclib and Anastrozole. Further neoadjuvant studies are required however the potential addition of Abemaciclib to ET and would improve our management options in synchronous cancer patients.

Potential Neoadjuvant Chemotherapy Alternatives

The combination of Gemcitabine plus nanoparticle albumin-bound (nab)-Paclitaxel (GA) have been evaluated as first line regimens for both metastatic pancreatic adenocarcinoma and breast cancer. In both cancer sub-sets, the efficacy of the combination chemotherapy has been proven. However, they are not indicated as first line treatments in either cancer.

In pancreatic adenocarcinoma, a case series compared 485 consecutive patients receiving either FOLFIRINOX or GA as first line treatment (45). They noted FOLFIRINOX was associated with higher partial response evaluation criteria in solid tumours (RECIST) rates (19% versus 6%, p = 0.001). In propensity-score matched analysis, FOLFIRINOX patients had higher response rates (19% versus 6%, p = 0.001) and were more likely to undergo pancreatectomy (29% vs 18%, p = 0.02). Overall survival though, was comparable between either chemotherapy regimen.

Gemcitabine has limited use in the metastatic breast cancer setting. The current indication for its use (Gemcitabine and carboplatin) is relegated to patients who have already had first line treatment (anthracycline and taxane), or to those for whom there is a contraindication to an anthracycline and/or taxane only (46). The addition of Gemcitabine to standard anthracycline and taxane chemotherapy has been evaluated, and failed to show any improvement in 5-year DFS or OS (47).

CONCLUSION

Synchronous breast and pancreatic breast cancers are rare, with literature limited to case reports only currently. Neoadjuvant therapy in both cancers, has resulted in significant improvements in the outcomes for patients in each individual cancer. However, there is no single neoadjuvant regimen that is shown to completely manage both. From our experience, we have noted that the typically less aggressive of the two cancers, the breast cancer, can direct our management due to the wider scope of treatment. In Luminal breast cancers, we can provide NET concurrently with our pancreatic chemotherapy regimen. However, in HER2+ or TNBC, the inability to provide any concurrent treatment to the breast results in our requirement of upfront surgery. Given how rapidly breast cancer management is evolving, we hope that further biologic treatments would wide our treatment options even greater in these complex synchronous cancer situations. However, given the paucity of the data, further research is required to determine whether the breast pathology, rather than pancreatic, should direct treatment.
DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because the data is not anonymized given the 2 complex cases. Requests to access the datasets should be directed to Adam Ofri, adamofri@gmail.com.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

REFERENCES

1. Toesca DAS, Koong AJ, Poulsides GA, Visser BC, Haraldsdottir S, Koong AC, et al. Management of borderline resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. (2018) 100(5):1155–74. doi: 10.1016/j.ijrobp.2017.12.287
2. Chawla A, Molina G, Pak LM, Rosenthal M, Mancias JD, Clancy TE, et al. Neoadjuvant therapy is associated with improved survival in borderline-resectable pancreatic cancer. Ann Surg Oncol. (2020) 27(4):1191–200. doi: 10.1245/s10434-019-08087-z
3. Heinrich S, Bessellink M, Moehler M, Van Laethem JL, Durece M, Grimminger P, et al. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. (2019) 19(1):1–9. doi: 10.1186/s12885-019-5889-5
4. Balaban EP, Mangu PB, Khoraana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. (2016) 34(22):2654–68. doi: 10.1200/JCO.2016.67.5561
5. Castro M, Vierkkoetter K, Prager D, Montgomery S, Sedgwick K. Synchronous onset of breast and pancreatic cancers: results of germline and somatic genetic analysis. Case rep oncol. (2016) 9(2):387–94. doi: 10.1159/000447348
6. Eriko K, Šimšek G, Dereli Ç, Tavlı Ş. Synchronous adenocarcinoma and breast infiltrative ductal carcinoma. Electron J Gen Med. (2014) 11(Suppl. 1):51–3. doi: 10.15197/tababd.1.11.32
7. Binkan AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. (2012) 491(7424):399–405. doi: 10.1038/nature11547
8. Salo-Mullen EE, O’Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. (2015) 121(24):4382–8. doi: 10.1002/cncr.29664
9. Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects. Cancer Manage Res. (2020) 12:2731–42. doi: 10.2147/CMAR.S211151
10. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. (2016) 16(2):110–20. doi: 10.1038/nrc.2015.21
11. Binder KAR, Mick R, O’Hara M, Teitelbaum U, Karasic T, Schneider C, et al. Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. AACR (2019).
12. Golain T, Varadbachary GR, Sela T, Fogelman DR, Halperin N, Shroff RT, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. Am Soc Clin Oncol. (2018) (Suppl. 4):297. doi: 10.15107/sabad.1.11.32
13. Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. (2019) 39:79–86. doi: 10.1200/EDBC_238977
14. Motheons J, Gee J. Understanding breast cancer: a guide for people with cancer, their families and friends. Cancer Council of New South Wale: Cancer council of NSW (2020).

AUTHOR CONTRIBUTIONS

Entire paper - AO, CD, AM Patient information and discussion - AS, MW, SS, JS, AG. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.858349/full#supplementary-material.
Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol.* (2008) 26 (5):778–85. doi: 10.1200/JCO.2007.10.0235

29. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. *J Natl Cancer Inst.* (2019) 111(8):782–94. doi: 10.1093/jnci/djz073

30. Conroy T, Hammel P, Hebbel M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med.* (2018) 379(25):2395–406. doi: 10.1056/NEJMoa1809775

31. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet.* (2012) 379(9814):432–44. doi: 10.1016/S0140-6736(11)61625-5

32. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. *JAMA Oncol.* (2016) 2(6):751–60. doi: 10.1001/jamaoncol.2015.6113

33. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet.* (2012) 379(9814):432–44. doi: 10.1016/S0140-6736(11)61625-5

34. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. *JAMA Oncol.* (2016) 2 (11):1477–86. doi: 10.1001/jamaoncol.2016.1897

35. Palmieri C, Cleator S, Kilburn LS, Kim SB, Alvarado G, Bertrand AD, et al. NEOCREST: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. *Breast Cancer Res Treat.* (2014) 148 (3):581–90. doi: 10.1007/s10549-014-3183-4

36. Alba E, Calvo L, Albanel J, De la Haba JR, Arcusa Lanza A, Chacon JL, et al. Chemotherapy (CT) and hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. *Ann Oncol.* (2012) 23 (12):3069–74. doi: 10.1093/annonc/mds132

37. Shimamura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Arai T, et al. Dramatic response of FOLFIRINOX regimen in a collagen pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. *Jpn J Clin Oncol.* (2019) 49(11):1049–54. doi: 10.1093/jjco/hyz141

38. Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus chemotherapy alone for early HER2-positive breast cancer: results of the neoMONARCH phase II neoadjuvant study in HR(+)HER2(-) breast cancer. *Clin Cancer Res.* (2020) 26 (3):566–80. doi: 10.1158/1078-0432.CCR-19-1425

39. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HER2+, node-positive, high-risk, early breast cancer (monarchE). *J Clin Oncol.* (2020) 38(34):3987–98. doi: 10.1200/JCO.20.02514

40. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, et al. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. *JAMA Surg.* (2020) 155(9):832–9. doi: 10.1001/jamasurg.2020.2286

41. NSW. CJ. Breast metastatic eRBB2plain and gemcitabine. (2021). Available from: https://www.eviq.org.au/medical-oncology/breast/metastatic/1324-breast-metastatic-carboplatin-and-gemcitabine#indications-and-patient-population

42. de Gregorio A, Habeber L, Fasching PA, Muller V, Schrader I, Lorenz R, et al. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res.* (2020) 22(1):111. doi: 10.1186/s13058-020-01348-w

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ofri, Zuidersma, Diakos, Stevanovic, Wong, Sood, Samra, Gill and Mittal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which does not comply with these terms.